Evidence gap
The answer is genuinely unknown — a pending outcome trial will settle it.
Resolves via: Resolving-trial readout
How cardiologists read the fine print of one guideline decides whether millions of heart attack patients get a year of dual antiplatelet therapy or an early de-escalation — and which P2Y12 drug they walk out on.
Active since Jan 2025
The debate
10 clinicians quoted on the record
The guideline carries competing Class 1 recommendations — a full year of dual antiplatelet therapy to cut ischemic events alongside shortening or de-escalating it to cut bleeding — and clinicians can't apply both, so the document needs clarification before it drives practice.
“The 2025 ACC/AHA ACS guidelines remain an area that's still controversial.”
“The 2025 ACC/AHA ACS guidelines remain an area that's still controversial.”
+ 3 more on this side
Merging STEMI and NSTEMI into one framework finally aligns practice with a decade of trials, and the flexibility clinicians read as 'conflict' is really room to individualize between ischemic and bleeding risk.
“unclear”
“By grouping STEMI and NSTEMI together, she added, “I’m really hoping that it’s going to make everybody much more comfortable because we had clinical trials that came out, but the guidelines were so out of date.””
+ 1 more on this side
Where the experts land
5–3 on record · 2 unplaced
Fix the conflicts first · 5
On the record, unplaced · 2
Unified guideline is progress · 3
“some recommendations may benefit from clarification to improve internal alignment. For example, the guideline includes Class 1 recommendations both for DAPT for 1 year (to reduce ischemic events) and for switching to ticagrelor monotherapy after 1 month of tolerating DAPT (to red”
Where the field stands
Common ground
Everyone agrees one combined ACS document was overdue and that several of its new recommendations are genuine advances.
The crux
Whether the early beta-blocker recommendation — and the document's internal inconsistencies — deserve a formal correction now, or can wait for the normal revision cycle.
Still unknown
A clear read from the contemporary beta-blocker trials, separating the acute first-day dose from long-term continuation in revascularized patients.
On the record
Their own words — position stated as published
complete revascularization
“A strategy of complete revascularization is recommended in patients with ST-segment elevation myocardial infarction or non–ST-segment elevation ACS.”
Rao SV · Guideline writing committee chair · AHA Journals ↗
caution outside proven shock criteria
“The current guidelines rightly -- American and European -- remain cautious with the class 2b recommendations, reflecting a field where clinical enthusiasm has clearly outpaced high quality evidence.”
Roxana Mehran · Mount Sinai; ACC discussant · MedPage Today ↗
Where do you land?
No votes yet — the measured split appears at 10.
Where the evidence stands
The 2025 ACS guideline elevated early oral beta-blocker to Class 1, LOE A. A JACC critique argued that recommendation rests on old data, conflicts with later neutral studies, and should have been Class 2b or 3 pending REBOOT/BETAMI/DANBLOCK. O'Donoghue notes the document was locked before the 2025 trials. Acute initiation versus long-term continuation are being conflated in practice.
What's settled
4What's still open
4How this gets settled
The answer is genuinely unknown — a pending outcome trial will settle it.
What tips it: In patients with NSTE-ACS, routine pretreatment with a P2Y12 inhibitor before assessment of coronary anatomy is not supported by current evidence but it may be considered if invasive management is delayed and the patient is not at high bleeding risk.
Who could settle it
Know an expert who could settle this? Suggest one →
Who this affects
Who could fund or run it
Institutions that could fund, run, or adopt
Sources & verification
+ 54 more, each dated and verification-tagged
Who we found publicly on the record — a snapshot, not a poll of the field. Larger dots are deciders; dashed dots are scan-reported, not yet verified.